Anti-Human IL17A Therapeutic Antibody (Secukinumab)

Figure 1 The Immunostaining of IL17 receptors are expressed in human astrocytes.

Scale bar 20 um, Hoechst was used as nuclear stain.

Elain, G., Jeanneau, K., Rutkowska, A., Mir, A. K., & Dev, K. K. (2014). The selective anti‐IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A‐induced levels of IL6 in human astrocytes. Glia, 62(5), 725-735.

Figure 2 FACs analysis of IL17 receptors are expressed in human astrocytes.

The data showed expression of IL17RA and IL17RC in human astrocytes.

Elain, G., Jeanneau, K., Rutkowska, A., Mir, A. K., & Dev, K. K. (2014). The selective anti‐IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A‐induced levels of IL6 in human astrocytes. Glia, 62(5), 725-735.

Figure 3 ELISA analysis of IL17A expression in mouse astrocytes.

IL17A increases the levels of IL6 in mouse astrocytes.

Elain, G., Jeanneau, K., Rutkowska, A., Mir, A. K., & Dev, K. K. (2014). The selective anti‐IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A‐induced levels of IL6 in human astrocytes. Glia, 62(5), 725-735.

Figure 4 Effects of Secukinumab on IL17A/TNFa-induced NF-jB activation.

The differences between treated and nontreated cells can be more easily seen in the black
and white "co-localizing pixels" where only the nuclei can be seen and the intensity of white is proportional to the amount of NFkB
present in these nuclei.

Elain, G., Jeanneau, K., Rutkowska, A., Mir, A. K., & Dev, K. K. (2014). The selective anti‐IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A‐induced levels of IL6 in human astrocytes. Glia, 62(5), 725-735.

Figure 1 Anti-Human IL17A Antibody (TAB-069) in ELISA

ELISA analysis of TAB-069 was performed by coating with Human IL17A Protein (No Tag). Then blocked with BSA and incubated with TAB-069. The HRP-conjugated goat anti-human IgG as a secondary antibody (1: 5000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.

Figure 2 Anti-Human IL17A Antibody (TAB-069) in WB

Western blot analysis of TAB-069 was performed with Human IL17A Protein (No Tag) in reduced condition Lane 1, Lane 2 and Lane 3 (0.1 μg, 0.3 μg and 0.6 μg respectively) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with TAB-069 (2 μg/mL) and HRP-conjugated goat anti-human IgG as a secondary antibody (1: 6000). Chemiluminescent detection was performed.

Figure 3 Anti-Human IL17A Antibody (TAB-069) in DB

Dot Blot analysis of TAB-069 was performed by coating with Human IL17A Protein (No Tag).

TAB-069 incubation concentration: 2 μg/mL.
HRP goat anti-human IgG as a secondary antibody (1: 6000)

NC: Negative control PC: Positive control